1. Home
  2. Live Updates
  3. Hematologic oncology

Page 2 - Hematologic Oncology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hematologic oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hematologic Oncology Today - Breaking & Trending Today

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology. ....

United States , Wesley Center , Case Western Reserve University , Leland Metheny , University Hospitals Cleveland Medical Center , Case Western Reserve University School Of Medicine , Oncology Program At Case Comprehensive Cancer Center , Seidman Cancer Center , Uh Wesley Center , University Hospitals Seidman Cancer Center , Science Summit , Case Western Reserve University School , Immune Oncology Program , Case Comprehensive Cancer Center , Seidman Cancer , Hematologic Oncology ,

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations. ....

Angelos Stergiou , Life Sciences Group , Sciences Group , Hematologic Oncology , Acute Myeloid Leukemia ,

Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL. ....

United States , Ibrahim Aldoss , Hematology Tissue Bank , Division Of Leukemia , Leukemia Research , Department Of Hematology , Gehr Family Center , Hematopoietic Cell Transplantation , Leukemia Registry , Hematologic Oncology , Onclive Tv , City Of Hope ,

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT

Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT. ....

Calvink Lee , Aacr Annual Meeting , Rgi 2001 , Hematologic Oncology , Phase 2b Rgi 2001 301 Trial Nct04014790 ,

Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL

Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia. ....

Jenniferr Brown , Chronic Lymphocytic Leukemia Center , Dana Farber Cancer Institute , Harvard Medical School , Margaret Collette Professor , Hematologic Oncology , Ash Annual Meeting , Chronic Lymphocytic Leukemia , Jennifer Brown ,